Browse this journal

Protein Kinase Inhibitors

Created 05 Mar 2024 | 4 articles

Edited by

Dr. Stefania Nobili(University of Florence, Italy)

Dr. Ida Landini(University of Florence, Italy)

Dr. Enrico Mini(University of Florence, Italy)

Download citations Download PDFs Download collection
Case Report
Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors
Marissa Meegdes, Marleen G. A. M. van der Velde, Sandra M. E. Geurts, Maartje A. C. E. van Kats, M. Wouter Dercksen & Vivianne C. G. Tjan-Heijnen

Originally published in Journal of Chemotherapy, Volume: 36, Number: 4 (18 May 2024)

Published online: 09 Nov 2023
AbstractforCase series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors | Full Text | References | PDF (1,008.9 KB) | EPUB
  • 786 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway
Fei Mao, Liangkui Gao, Liming Liu & Yuanjia Tang

Originally published in Journal of Chemotherapy, Volume: 36, Number: 3 (02 Apr 2024)

Published online: 02 Nov 2023
AbstractforEnhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 338 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Case Report
Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report
Qichen Zhang, Peng Xie, Xiaoming Hou, Chengpeng Zhao, Ling Duan & Hui Qiao

Originally published in Journal of Chemotherapy, Volume: 36, Number: 4 (18 May 2024)

Published online: 01 Nov 2023
AbstractforBenefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report | Full Text | References | PDF (1.8 MB) | EPUB
  • 609 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Sorafenib tosylate-loaded nanosuspension: preparation, optimization, and in vitro cytotoxicity study against human HepG2 carcinoma cells
Harpreet Kaur Khanuja, Rajendra Awasthi & Harish Dureja

Originally published in Journal of Chemotherapy, Volume: 36, Number: 4 (18 May 2024)

Published online: 25 Oct 2023
AbstractforSorafenib tosylate-loaded nanosuspension: preparation, optimization, and in vitro cytotoxicity study against human HepG2 carcinoma cells | Full Text | References | PDF (3.7 MB) | EPUB
  • 265 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access